TOKYO, Apr 02 (Pulse News Wire) – Shionogi & CO.,LTD. (4507.T) completed the acquisition of the Edaravon business from Daiichi Pharma and established a dedicated Radicava business unit.
Starting April 01, 2026, the company expects annual global revenue of approximately 43,330 million yen from the Edaravon product line. The newly formed Radicava business unit, based in Florham Park, New Jersey, operates as a wholly-owned subsidiary of Shionogi Inc. It will focus on the sales and distribution of Radicava, a treatment for Amyotrophic Lateral Sclerosis (ALS).
With this move, Shionogi strengthens its commercial foundation in the rare disease sector, particularly in the United States. Shionogi plans to contribute to patient care through continuous and stable treatment options. The company anticipates positive impacts on consolidated performance starting fiscal 2027, contributing to revenues and profits.
🟢 Confidence: High AI-translated content.